| 1 |
35000525 | Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. | 2022 Dec 31 |
2 |
| 2 |
34169240 | CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin. | 2021 Jun 25 |
1 |
| 3 |
34372559 | Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection. | 2021 Jul 13 |
1 |
| 4 |
30837643 | Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. | 2019 Mar 5 |
1 |
| 5 |
31209198 | Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. | 2019 Jun 17 |
2 |
| 6 |
29286153 | CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. | 2018 Mar |
1 |
| 7 |
28030798 | Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. | 2017 Feb 14 |
1 |
| 8 |
28625637 | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. | 2017 Jun |
2 |
| 9 |
28766886 | Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. | 2017 Aug |
1 |
| 10 |
26612134 | LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. | 2016 Feb |
5 |
| 11 |
27166183 | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2016 Jun 7 |
1 |
| 12 |
27286453 | UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. | 2016 Jul 12 |
2 |
| 13 |
27350064 | Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. | 2016 Oct |
3 |
| 14 |
27598338 | Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. | 2016 |
3 |
| 15 |
27829224 | Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. | 2016 Dec 20 |
1 |
| 16 |
25296725 | Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. | 2015 Jan |
3 |
| 17 |
26288133 | Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. | 2015 Nov |
2 |
| 18 |
24114124 | Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. | 2014 Apr |
7 |
| 19 |
24666335 | Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. | 2014 Sep |
3 |
| 20 |
24928205 | The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. | 2014 Sep |
6 |
| 21 |
24942404 | Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. | 2014 Oct |
2 |
| 22 |
22492020 | Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. | 2013 Feb |
1 |
| 23 |
23917378 | PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. | 2013 May |
1 |
| 24 |
24098799 | Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. | 2013 |
1 |